The board of directors of Sino Biopharmaceutical Limited announced that "Etoricoxib Tablets" (brand name: Kaixi (specifications: 30mg and 60mg), an oral analgesic developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Etoricoxib is the latest generation of selective cyclooxygenase-2 (COX-2) inhibitor. It has the effects of anti-inflammatory, analgesic and antipyretic, as well as less gastrointestinal adverse reactions. It is suitable for the treatment of symptoms and medical signs in the acute and chronic stages of osteoarthritis and treatment of acute gouty arthritis and primary dysmenorrhea. The Medication Guide for Gout by American College of Rheumatology recommends the use of Etoricoxib for the treatment of acute gouty arthritis. The Medication Guidelines for Osteoarthritis of China and the Expert Opinions on the Orthopedic Pain Management by the Orthopedic Branch of the Chinese Medical Association recommend patients with gastrointestinal risk to use selective COX-2 inhibitor, and Etoricoxib can be used. The approval of this product shall complement and enhance the Group's layout of non-steroidal anti- inflammatory drugs in the analgesic field, relieve pain and bring more treatment options for the majority of pain patients.